Next-generation XPO1 inhibitor shows improved efficacy and in vivo tolerability in hematological malignancies.

Abstract:

:The nuclear export receptor, Exportin 1 (XPO1), mediates transport of growth-regulatory proteins, including tumor suppressors, and is overactive in many cancers, including chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML) and aggressive lymphomas. Oral selective inhibitor of nuclear export (SINE) compounds that block XPO1 function were recently identified and hold promise as a new therapeutic paradigm in many neoplasms. One of these compounds, KPT-330 (selinexor), has made progress in Phase I/II clinical trials, but systemic toxicities limit its administration to twice-per-week and requiring supportive care. We designed a new generation SINE compound, KPT-8602, with a similar mechanism of XPO1 inhibition and potency but considerably improved tolerability. Efficacy of KPT-8602 was evaluated in preclinical animal models of hematological malignancies, including CLL and AML. KPT-8602 shows similar in vitro potency compared with KPT-330 but lower central nervous system penetration, which resulted in enhanced tolerability, even when dosed daily, and improved survival in CLL and AML murine models compared with KPT-330. KPT-8602 is a promising compound for further development in hematological malignancies and other cancers in which upregulation of XPO1 is seen. The wider therapeutic window of KPT-8602 may also allow increased on-target efficacy leading to even more efficacious combinations with other targeted anticancer therapies.

journal_name

Leukemia

journal_title

Leukemia

authors

Hing ZA,Fung HY,Ranganathan P,Mitchell S,El-Gamal D,Woyach JA,Williams K,Goettl VM,Smith J,Yu X,Meng X,Sun Q,Cagatay T,Lehman AM,Lucas DM,Baloglu E,Shacham S,Kauffman MG,Byrd JC,Chook YM,Garzon R,Lapalombella R

doi

10.1038/leu.2016.136

subject

Has Abstract

pub_date

2016-12-01 00:00:00

pages

2364-2372

issue

12

eissn

0887-6924

issn

1476-5551

pii

leu2016136

journal_volume

30

pub_type

杂志文章

相关文献

LEUKEMIA文献大全
  • Variant translocation t(3;15)(q21;q22) in a patient with acute promyelocytic leukemia.

    abstract::Bone marrow cells from most patients with acute promyelocytic leukemia contain a highly specific cytogenetic rearrangement, a reciprocal translocation between the long arms of chromosomes 15 and 17. Several cases of variant translocations involving 17q but not 15q have been reported, leading to the suggestion that the...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Heim S,Kristoffersson U,Mandahl N,Malm C,Mitelman F

    更新日期:1988-01-01 00:00:00

  • Redirection of CMV-specific CTL towards B-CLL via CD20-targeted HLA/CMV complexes.

    abstract::B-cell chronic lymphocytic leukaemia (B-CLL) is a slowly progressing malignancy of CD5(+) B cells, for which at present no curative treatment is available. In our current study, we apply a novel bridging reagent to redirect cytomegalovirus (CMV)-specific cytotoxic T lymphocytes (CTL) to target B-CLL. A streptavidin-fu...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2404185

    authors: Mous R,Savage P,Remmerswaal EB,van Lier RA,Eldering E,van Oers MH

    更新日期:2006-06-01 00:00:00

  • Cytokine enhancement of immunogenicity in chronic myeloid leukaemia.

    abstract::Various clinical and laboratory observations suggest that the leukaemia cells in chronic myeloid leukaemia (CML) are potentially immunogenic. Whilst the ability of the leukaemia cells to elicit an anti-leukaemic immune response in the allogeneic setting is established, it remains unclear why such anti-leukaemic respon...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2400858

    authors: Coleman S,Throp D,Fisher J,Bailey-Wood R,Lim SH

    更新日期:1997-12-01 00:00:00

  • Suppression of G-CSF-mediated Stat signalling by IL-3.

    abstract::G-CSF-induced myeloid differentiation of 32Dcl3 murine myeloblast cells is antagonized by concurrent exposure to interleukin-3 (IL-3) or by oncogenic transformation of 32Dcl3 by src- or abl-oncogenes which render the cells IL-3-independent. Recent reports have linked G-CSF-mediated differentiation to the ability of G-...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2401253

    authors: Steinman RA,Iro A

    更新日期:1999-01-01 00:00:00

  • Somatic hypermutation targeting to intrinsic hotspots of immunoglobulin genes in follicular lymphoma and multiple myeloma.

    abstract::In this study, we analyzed the targeting of the somatic hypermutation (SHM) mechanism at specific hotspot sequence motifs in the V(H) and Vkappa genes of 10 follicular lymphoma (FL) cases and the Vkappa and Vlambda genes of 11 kappa- and six lamda-light chain expressing multiple myeloma (MM) cases. These sequences wer...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2402258

    authors: Belessi C,Stamatopoulos K,Stavroyianni N,Zoi K,Papadaki T,Kosmas C

    更新日期:2001-11-01 00:00:00

  • CD44 isoforms distinguish between bone marrow plasma cells from normal individuals and patients with multiple myeloma at different stages of disease.

    abstract::CD44 variant isoforms (CD44v) have been shown to be important factors in adverse prognosis in hematological malignancies. To investigate whether CD44 expression is associated with malignant transformation in multiple myeloma, RNA and protein expression of CD44 standard (CD44s) and CD44v4, v6, v9, v10 containing isofor...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2401179

    authors: van Driel M,Günthert U,Stauder R,Joling P,Lokhorst HM,Bloem AC

    更新日期:1998-11-01 00:00:00

  • Harmonization of molecular monitoring of CML therapy in Europe.

    abstract::The high efficacy of the standard treatment of chronic myeloid leukemia (CML) with imatinib has prompted the need for accurate methods to monitor response at levels below the landmark of complete cytogenetic remission. Quantification of BCR-ABL transcripts has proven to be the most sensitive method available, and has ...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:10.1038/leu.2009.168

    authors: Müller MC,Cross NC,Erben P,Schenk T,Hanfstein B,Ernst T,Hehlmann R,Branford S,Saglio G,Hochhaus A

    更新日期:2009-11-01 00:00:00

  • Clonal diversity predicts adverse outcome in chronic lymphocytic leukemia.

    abstract::Genomic analyses of chronic lymphocytic leukemia (CLL) identified somatic mutations and associations of clonal diversity with adverse outcomes. Clonal evolution likely has therapeutic implications but its dynamic is less well studied. We studied clonal composition and prognostic value of seven recurrently mutated driv...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/s41375-018-0215-9

    authors: Leeksma AC,Taylor J,Wu B,Gardner JR,He J,Nahas M,Gonen M,Alemayehu WG,Te Raa D,Walther T,Hüllein J,Dietrich S,Claus R,de Boer F,de Heer K,Dubois J,Dampmann M,Dürig J,van Oers MHJ,Geisler CH,Eldering E,Levine RL

    更新日期:2019-02-01 00:00:00

  • Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS).

    abstract::Current guidelines for smoldering multiple myeloma (SMM) recommend active monitoring until the onset of multiple myeloma (MM) before initiating treatment or enrollment in a clinical trial. Earlier intervention may delay progression to MM. In CENTAURUS, 123 patients with intermediate-risk or high-risk SMM were randomly...

    journal_title:Leukemia

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1038/s41375-020-0718-z

    authors: Landgren CO,Chari A,Cohen YC,Spencer A,Voorhees P,Estell JA,Sandhu I,Jenner MW,Williams C,Cavo M,van de Donk NWCJ,Beksac M,Moreau P,Goldschmidt H,Kuppens S,Bandekar R,Clemens PL,Neff T,Heuck C,Qi M,Hofmeister CC

    更新日期:2020-07-01 00:00:00

  • Bone marrow plasma cells 20% or greater discriminate presentation, response, and survival in AL amyloidosis.

    abstract::We explored the association between bone marrow plasma cells (BMPCs) and disease presentation and outcome among 1574 AL patients. Three BMPC groups were formulated: <5% (n = 231, 15% of study population), 5-19% (n = 1045, 66%), and ≥20% (n = 298, 19%). Heart and renal involvement were more and less prevalent, respecti...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/s41375-019-0655-x

    authors: Muchtar E,Gertz MA,Kourelis TV,Sidana S,Go RS,Lacy MQ,Buadi FK,Dingli D,Hayman SR,Kapoor P,Leung N,Fonder A,Hobbs M,Lisa Hwa Y,Gonsalves W,Warsame R,Russell S,Lust JA,Lin Y,Zeldenrust S,Rajkumar SV,Kyle RA,Kum

    更新日期:2020-04-01 00:00:00

  • Treatment of resistant disease.

    abstract::Resistant AML encompasses two groups of patients: those with refractory leukemia and those whose leukemia has relapsed. Refractory leukemia is disease that does not respond to initial induction chemotherapy with cytarabine and an anthracycline. Patients with refractory leukemia are likely to have disease with adverse ...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:

    authors: Schiller GJ

    更新日期:1998-09-01 00:00:00

  • FHL2 regulates hematopoietic stem cell functions under stress conditions.

    abstract::FHL2, a member of the four and one half LIM domain protein family, is a critical transcriptional modulator. Here, we identify FHL2 as a critical regulator of hematopoietic stem cells (HSCs) that is essential for maintaining HSC self-renewal under regenerative stress. We find that Fhl2 loss has limited effects on hemat...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2014.254

    authors: Hou Y,Wang X,Li L,Fan R,Chen J,Zhu T,Li W,Jiang Y,Mittal N,Wu W,Peace D,Qian Z

    更新日期:2015-03-01 00:00:00

  • Long-term follow-up of patients with newly diagnosed adult acute lymphoblastic leukemia: a single institution experience of 378 consecutive patients over a 21-year period.

    abstract::Although the prospect of long-term leukemia-free survival (LFS) after treatment for adult acute lymphoblastic leukemia (ALL) is widely accepted, few studies have reported long-term survival data. Three hundred and seventy-eight ALL patients, referred to our hospital from 1978 to 1999, were reviewed for long-term follo...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2402289

    authors: Thomas X,Danaïla C,Le QH,Sebban C,Troncy J,Charrin C,Lhéritier V,Michallet M,Magaud JP,Fiere D

    更新日期:2001-12-01 00:00:00

  • Secondary chromosomal abnormalities in acute leukemias.

    abstract::Secondary chromosomal aberrations reported in the literature were surveyed in acute myeloid or lymphoblastic leukemia (AML or ALL) with one of the following primary abnormalities: in AML, t(1;3), t(1;22), der(1;7), inv(3), t(3;5) +4, del(5q), t(6;9), -7, t(7;11), del(7q), +8, t(8;16), t(8;21), +9, t(9;11), del(9q), t(...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Johansson B,Mertens F,Mitelman F

    更新日期:1994-06-01 00:00:00

  • Mutational and expression analysis of the chromosome 12p candidate tumor suppressor genes in pre-B acute lymphoblastic leukemia.

    abstract::Allelic losses on chromosome 12p12-13 are associated with childhood acute lymphoblastic leukemia (ALL) and several solid neoplasias, suggesting the presence of a tumor suppressor locus. The recent construction of a transcription map of this locus has enabled the identification of eight genes, of which five were previo...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2403441

    authors: Montpetit A,Larose J,Boily G,Langlois S,Trudel N,Sinnett D

    更新日期:2004-09-01 00:00:00

  • Expression of p16INK4A and p14ARF in hematological malignancies.

    abstract::The INK4A/ARF locus yields two tumor suppressors, p16INK4A and p14ARF, and is frequently deleted in human tumors. We studied their mRNA expressions in 41 hematopoietic cell lines and in 137 patients with hematological malignancies; we used a quantitative reverse transcription-PCR assay. Normal peripheral bloods, bone ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2401557

    authors: Taniguchi T,Chikatsu N,Takahashi S,Fujita A,Uchimaru K,Asano S,Fujita T,Motokura T

    更新日期:1999-11-01 00:00:00

  • The role of TGFβ in hematopoiesis and myeloid disorders.

    abstract::The role of transforming growth factor-β (TGFβ) signaling in embryological development and tissue homeostasis has been thoroughly characterized. Its canonical downstream cascade is well known, even though its true complexity and other non-canonical pathways are still being explored. TGFβ signaling has been described a...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:10.1038/s41375-019-0420-1

    authors: Bataller A,Montalban-Bravo G,Soltysiak KA,Garcia-Manero G

    更新日期:2019-05-01 00:00:00

  • A 3-day schedule of fludarabine in previously treated chronic lymphocytic leukemia.

    abstract::This study was undertaken to determine the efficacy and toxicity of a shorter schedule of fludarabine administration (30 mg/m2 i.v. daily for 3 days every 4 weeks) in patients with previously treated chronic lymphocytic leukemia (CLL). Eighty patients with previously treated advanced (Rai III-IV) (54%) or progressive ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Robertson LE,O'Brien S,Kantarjian H,Koller C,Beran M,Andreeff M,Lerner S,Plunkett W,Keating MJ

    更新日期:1995-09-01 00:00:00

  • Adult T-cell acute lymphoblastic leukemias with IL7R pathway mutations are slow-responders who do not benefit from allogeneic stem-cell transplantation.

    abstract::The prognostic value of IL7-receptor pathway (IL7Rp) mutations in T-cell acute lymphoblastic leukemia (T-ALL) remains unclear. We performed a comprehensive study of 200 adult patients with T-ALL included in the GRAALL2003/2005 protocols to address the clinical significance of IL7Rp mutations. Next-generation sequencin...

    journal_title:Leukemia

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1038/s41375-019-0685-4

    authors: Kim R,Boissel N,Touzart A,Leguay T,Thonier F,Thomas X,Raffoux E,Huguet F,Villarese P,Fourrage C,Passini L,Hunault M,Lepretre S,Chevallier P,Braun T,Lhéritier V,Chantepie S,Maury S,Escoffre M,Tavernier E,Chalandon

    更新日期:2020-07-01 00:00:00

  • Cellular and molecular studies on the early stages of human hematopoietic differentiation in culture of pure progenitors.

    abstract::Methodology has been developed that enables virtually complete purification and recovery of early hematopoietic progenitors from human adult blood, a minority of which is multipotent and endowed with self-renewal capacities, i.e., exhibits stem cell properties. This report briefly reviews: (i) the key steps involved i...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Pelosi E,Testa U,Gabbianelli M,Valtieri M,Montesoro E,Samoggia P,Mastroberardino G,Isacchi G,Peschle C

    更新日期:1992-11-01 00:00:00

  • Cancer procoagulant in the human promyelocytic cell line NB4 and its modulation by all-trans-retinoic acid.

    abstract::Acute promyelocytic leukemia (APL) cells express different types of procoagulant activity (PCA), including tissue factor (TF), and cancer procoagulant (CP). The aim of this study was to investigate whether the NB4 cell line, the first ever isolated human APL line, with the typical t(15;17) chromosomal balance transloc...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Falanga A,Consonni R,Marchetti M,Mielicki WP,Rambaldi A,Lanotte M,Gordon SG,Barbui T

    更新日期:1994-01-01 00:00:00

  • Treatment of neutropenia-related fungal infections with granulocyte colony-stimulating factor-elicited white blood cell transfusions: a pilot study.

    abstract::Neutropenia-related fungal infections can be life-threatening despite antifungal therapy. We evaluated the role of recombinant granulocyte colony-stimulating factor (rG-CSF)-elicited white blood cell (WBC) transfusions in patients with neutropenia-related fungal infections. Adult patients with hematologic malignancies...

    journal_title:Leukemia

    pub_type: 临床试验,杂志文章

    doi:10.1038/sj.leu.2400811

    authors: Dignani MC,Anaissie EJ,Hester JP,O'Brien S,Vartivarian SE,Rex JH,Kantarjian H,Jendiroba DB,Lichtiger B,Andersson BS,Freireich EJ

    更新日期:1997-10-01 00:00:00

  • Treatment results of three consecutive Brazilian cooperative childhood ALL protocols: GBTLI-80, GBTLI-82 and -85. ALL Brazilian Group.

    abstract::The Brazilian Cooperative Group for Treatment of Childhood Acute Lymphocytic Leukemia (GBTLI) has started clinical activities trials in 1980. Three consecutive multicenter studies in children with unprevious treated ALL have been completed including 994 patients. The first GBTLI-80 accrued 203 children from 1980 to 19...

    journal_title:Leukemia

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:

    authors: Brandalise S,Odone V,Pereira W,Andrea M,Zanichelli M,Aranega V

    更新日期:1993-08-01 00:00:00

  • Histone deacetylase inhibitors are the potent inducer/enhancer of differentiation in acute myeloid leukemia: a new approach to anti-leukemia therapy.

    abstract::We investigated the effect of the histone deacetylase inhibitors (HDIs), trichostatin A and trapoxin A on leukemia cells and cell lines from the viewpoint of differentiation induction. TSA induced differentiation in erythroid cell lines by itself, whereas it synergistically enhanced the differentiation that was direct...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2401508

    authors: Kosugi H,Towatari M,Hatano S,Kitamura K,Kiyoi H,Kinoshita T,Tanimoto M,Murate T,Kawashima K,Saito H,Naoe T

    更新日期:1999-09-01 00:00:00

  • Examination of a role for idiotypy in the disease remission of a long-term survivor of adult T cell leukemia treated with anti-Tac antibody.

    abstract::The alpha chain of the interleukin 2 receptor (IL2R alpha; Tac) was targeted in clinical trials with adult T cell leukemia using murine anti-Tac antibody. Of 19 patients, a single individual achieved a durable complete remission. The mechanism of this action by murine anti-Tac has not been defined. We examined the hyp...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2401048

    authors: Kingsbury GA,Waldmann TA,Junghans RP

    更新日期:1998-06-01 00:00:00

  • Genomic approaches to small molecule discovery.

    abstract::With the sequencing of the human genome and the development of new genomic technologies, biomedical discovery has been transformed. The applications of these new approaches are ever-expanding from disease classification, to identification of new targets, to outcome prediction. A logical next step is the integration of...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:10.1038/leu.2009.29

    authors: Stegmaier K

    更新日期:2009-07-01 00:00:00

  • Escalating the intensity of post-remission therapy improves the outcome in acute myeloid leukemia: the ECOG experience. The Eastern Cooperative Oncology Group.

    abstract::These ECOG trials have demonstrated that progressive increments in the intensity of post-remission therapy result in improving long-term, disease-free survival in adults with AML. The median duration of disease-free survival and long-term outcome from different post-remission therapies are summarized in Table 4. [tabl...

    journal_title:Leukemia

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:

    authors: Cassileth PA,Andersen JW,Bennett JM,Harrington DP,Hines JD,Lazarus HM,Mazza JJ,McGlave PP,O'Connell MJ,Paietta E

    更新日期:1992-01-01 00:00:00

  • Functional inactivation of wild-type p53 protein correlates with loss of IL-2 dependence in HTLV-I transformed human T lymphocytes.

    abstract::Human T cell leukemia virus type-I (HTLV-I), the etiologic agent of adult T cell leukemia (ATL) transforms human T cells in vitro and in vivo. Tax, the major transactivator of HTLV-I is critical for the initial events involved in transformation, however, the later steps required for progression from an IL-2 dependent ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Gartenhaus RB,Wang P

    更新日期:1995-12-01 00:00:00

  • Characterization of the immunoglobulin light chain variable region gene expressed in multiple myeloma.

    abstract::We studied the organization, diversification and clinical significance of the immunoglobulin light chain (IgL) variable region genes expressed in 17 kappa-chain and 16 lambda-chain producing multiple myeloma (MM) samples. The V genes from 31 MM samples had over 84.9% homology to the known germline Vkappa/lambda genes,...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2400972

    authors: Kiyoi H,Naito K,Ohno R,Saito H,Naoe T

    更新日期:1998-04-01 00:00:00

  • Constitutive expression of GM-CSF mRNA by CML blast cells is correlated with endogenous megakaryocytic colony formation.

    abstract::Purified blast cells from peripheral blood of 12 patients, with chronic myelogenous leukemia (CML) in chronic phase, were analyzed for the constitutive expression of the granulocyte-macrophage colony-stimulating factor (GM-CSF) transcript. Seven out 12 patients exhibited the specific 1.0 kb GM-CSF mRNA. Six from these...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Lajmanovich A,Berthier R,Schweitzer A,Leger J,Hollard D

    更新日期:1993-08-01 00:00:00